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Schizophrenia is a common disorder with high heritability and a 10-fold increase in risk to siblings of probands.
Replication has been inconsistent for reports of significant genetic linkage. To assess evidence for linkage across
studies, rank-based genome scan meta-analysis (GSMA) was applied to data from 20 schizophrenia genome
scans. Each marker for each scan was assigned to 1 of 120 30-cM bins, with the bins ranked by linkage scores
(1 p most significant) and the ranks averaged across studies (Ravg) and then weighted for sample size
( ). A permutation test was used to compute the probability of observing, by chance, each bin’sN[affected cases]
average rank (PAvgRnk) or of observing it for a bin with the same place (first, second, etc.) in the order of average
ranks in each permutation (Pord). The GSMA produced significant genomewide evidence for linkage on chromosome
2q ( ). Two aggregate criteria for linkage were also met (clusters of nominally significant P valuesP ! .000417AvgRnk
that did not occur in 1,000 replicates of the entire data set with no linkage present): 12 consecutive bins with both
PAvgRnk and , including regions of chromosomes 5q, 3p, 11q, 6p, 1q, 22q, 8p, 20q, and 14p, and 19P ! .05ord
consecutive bins with , additionally including regions of chromosomes 16q, 18q, 10p, 15q, 6q, and 17q.P ! .05ord
There is greater consistency of linkage results across studies than has been previously recognized. The results suggest
that some or all of these regions contain loci that increase susceptibility to schizophrenia in diverse populations.
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Introduction
Schizophrenia (SCZ; locus SCZD [MIM #181500]) is a
common disorder with a heritability of 0.70–0.85 and
a 10-fold increase in risk to siblings of probands (Lev-
inson and Mowry 2000). A large number of genome
scan projects have been completed (see below). Ge-
nomewide significant evidence for linkage has been re-
ported in three chromosomal regions, each with some
degree of support in other data sets. In a study of 265
Irish pedigrees, Straub et al. (1995) reported a LOD
score of 3.51 on chromosome 6p24-22, a region where
evidence for linkage was also reported by Moises et al.
(1995), Maziade et al. (2001), Lindholm et al. (2001),
Schwab et al. (2000), and a multicenter analysis (Schizo-
phrenia Linkage Collaborative Group for Chromosomes
3, 6 and 8 [hereafter referred to as “SLCG”] 1996).
Straub et al. (2002a) recently presented evidence sup-
porting dysbindin (DTNBP1; 6p22.3) as an SCZ can-
didate gene in this region. In 54 European-ancestry ped-
igrees, Blouin et al. (1998) reported a nonparametric
linkage (NPL) score (Zall) of 4.18 ( ) on chro-P ! .00002
mosome 13q32, as well as positive evidence for linkage
in 51 additional pedigrees, with a second report of sig-
nificant evidence for linkage ( ) in 22 Ca-Z p 4.42max
nadian pedigrees (Brzustowicz et al. 1999). In the same
Canadian data set, Brzustowicz et al. (2000) reported a
Zmax of 6.50 on chromosome 1q21-22 (D1S1679), and
Gurling et al. (2001) reported supportive evidence in the
region in 13 U.K. and Icelandic pedigrees. In two other
regions, several groups have produced highly suggestive
evidence for linkage. On chromosome 8p21-22, Blouin
at al. (1998) reported a Zall of 3.64, with support from
Brzustowicz et al. (2000), Gurling et al. (2001), Kendler
et al. (1996), a multicenter analysis (SLCG 1996), and
Stefansson et al. (2002). The latter group also presented
evidence for NRG1 (8p21-p12; neuregulin 1) as an SCZ
candidate gene, although it is located 9–13 cM cen-
tromeric to other maximal linkage results. Finally, Cao
et al. (1997) reported suggestive evidence for linkage on
chromosome 6q21-22.3 ( ), a finding sup-Pp .00024
ported by data from the National Institute of Mental
Health (NIMH) Genetics Initiative data set (Martinez et
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al. 1999), a multicenter analysis (Levinson et al. 2000),
and Lindholm et al. (2001).
None of these regions has produced strong support
for linkage in the majority of genome scan projects.
There are many possible explanations for this inconsis-
tency of results, such as genotyping and diagnostic er-
rors, differences in statistical strategies, or true differ-
ences in genetic effects of these and other loci across
ethnic groups or types of pedigrees. Given the large
number of projects and analyses that have been under-
taken, spurious findings could also be reported several
times (Lander and Kruglyak 1995). Another possibility
is that each of these loci has a small populationwide
effect on susceptibility and is thus difficult to detect
consistently without very large samples. Suarez et al.
(1994) demonstrated this problem in a simulation study
of polygenic disease models, and Go¨ring et al. (2001)
recently showed that, for small genetic effect sizes, ge-
nome scans of pedigree samples with low power tend
to overestimate the genetic effects at loci with the high-
est scores in the scan—that is, genetic parameters have
effectively been maximized. This would be true whether
a locus had a small effect on risk in each individual
carrier (polygene model) or a larger effect on risk in a
small proportion of cases (locus heterogeneity model).
Thus, although optimistic observers might conclude
that strong evidence has been emerging for linkage to
SCZ in a number of chromosomal regions, skeptics have
been more impressed by the many failures to replicate
SCZ linkage findings. A major difficulty here is that SCZ
genome scan sample sizes have been small—the largest
scan included 294 small pedigrees (DeLisi et al. 2002b),
and the typical sample has been 20–100, whereas sam-
ples of (for example) 600–1,000 affected sibling pairs
would be required to reliably demonstrate locus-specific
genetic effects causing a 27%–30% populationwide in-
crease in risk to siblings (Hauser et al. 1996), and there
are multiplicative gene effects that are even more dif-
ficult to detect (Rybicki and Elston 2000).
To address this problem, we applied the rank-based
genome scan meta-analysis (GSMA) method (Wise et
al. 1999) to data from the 20 complete genome scans
of SCZ described in table 1. The first article in this series
(Levinson et al. 2003 [in this issue]) described the
GSMA method in greater detail and presented a sim-
ulation study of the power of the method to detect link-
age in data sets resembling the SCZ and bipolar disorder
scans that we have studied. In brief, in GSMA, the au-
tosomes are divided into 30-cM bins, the evidence for
linkage in each study is rank-ordered across bins with
and without weights for sample size, and the average
ranks across studies are evaluated for statistically sig-
nificant evidence for linkage in several ways, as dis-
Table 1
Characteristics of SCZ Genome Scans
STUDY SITEa
FIRST
AUTHORb DIAGNOSTIC MODEL(S) (CRITERIA)c
NO. OFd
GENETIC
MODEL(S)e
TYPE OF
ANALYSIS PROGRAM
OUTPUT
USEDf
REPORTED
ETHNICITIESgPeds Aff Aff/Ped Markers
U.S./International DeLisi (1)1 SCZ,SA (D3R) 294 669 2.28 392 Nonpar Multipoint MM/Sibs MLS Eur, Chile
Finland-gen pop Paunio (1)2 SCZ; SA (D4) 185 390 2.11 398 Dom, Rec Single-point LINKAGE LOD Finland
Bonn Schwab3 SCZ,SA-S (RDC) 71 171 2.41 463 Nonpar Multipoint ASPEX MLS Ger, Seph, Hung
Cardiff Williams4 SCZ,SA (D4) 81 170 2.10 229 Nonpar Multipoint MM/Sibs MLS UK, Eire
MCV/Ireland (a) Straub5 SCZ,SA-PO (D3R) 77 179 2.32 383 Par (4) Single-point MENDEL HLOD Ireland
MCV/Ireland (b) Straub5 SCZ,SA-PO (D3R) 67 164 2.45 374 Par (4) Single-point MENDEL HLOD Ireland
MCV/Ireland (c) Straub5 SCZ,SA-PO (D3R) 74 169 2.28 385 Par (4) Single-point MENDEL HLOD Ireland
Johns Hopkins Blouin6 SCZ,SA (D4) 54 146 2.70 456 Nonpar Multipoint GH 1.1 NPL Eur-Am, Afr-Am
Costa Rica DeLisi (2)7 SCZ,SA (D4) 60 132 2.20 397 Nonpar Multipoint GH LOD Costa Rica
U.S./Australia Levinson8 SCZ,SA,PNOS (D3R) 43 126 2.93 310 Nonpar Multipoint GH 1.1 NPL Eur-Am, Afr-Am
Finland-isolate Paunio (2)2 SCZ; SA (D4) 53 113 2.13 398 Dom, Rec Single-point LINKAGE LOD Finland (isolate)
NIMH, Eur-Am Faraone9 SCZ,SA-D (D3R) 43 96 2.23 442 Nonpar Multipoint GH 1.1 NPL Eur-Am, Afr-Am
NIMH, Afr-Am Kaufmann10 SCZ,SA-D (D3R) 30 79 2.63 442 Nonpar Multipoint GH 1.1 NPL Afr-Am
Canada Brzustowicz11 SCZ,SA (D3R) 22 79 3.59 381 Dom, Rec Single-point FASTLINK HLOD Canada (Celtic)
Texas Garver12 SCZ (D4) 21 58 2.76 644 Nonpar Multipoint GH NPL Afr-Am, Eur-Am
UC London Gurling13 SCZ,SA,UFP (RDC) 13 56 4.31 365 Model-free Single-point MFLINK P values Iceland,UK
Sweden Lindholm14 SCZ; SA-D; PNOS; SA-B (D4) 1 43 43.00 352 Dom Single-point LINKAGE LOD Sweden
Kiel Moises15 SCZ,SA (RDC or D3R) 5 37 7.40 413 Nonpar Single-point WRPC P values Iceland
Utah Coon16 SCZ,SA-C (RDC) 9 35 3.89 329 Dom, Rec Single-point LINKAGE LOD Eur-Am
Palau Byerley17 SCZ,SA-S (RDC) 5 33 6.60 496 Dom, Rec Single-point LINKAGE LOD Palau
Total 1,208 2,945
a Sorted by decreasing number of affected cases, except for MCV/Ireland a/b/c.
b Superscripts indicate references as follows: 1 p DeLisi et al. (2002b); 2 p Paunio et al. (2001); 3 p Schwab et al. (2000); 4 p Williams et al. (1999); 5 p Straub et al.
(2002b); 6 p Blouin et al. (1998); 7 p DeLisi et al. (2002a); 8 p Levinson et al. (1998); 9 p Faraone et al. (1996); 10 p Kaufmann et al. (1998); 11 p Brzustowicz et al.
(2000); 12 p Garver et al. (2001); 13 p Gurling et al. (2001); 14 p Lindholm et al. (2001); 15 p Moises et al. (1995); 16 p Coon et al. (1994); 17 p Coon et al. (1998),
and W.B., unpublished data.
c D3R p DSM-IIIR criteria; D4 p DSM-IV; RDC p Research Diagnostic Criteria; SA p schizoaffective disorder (-S p SA-mainly schizophrenic; -D p SA-depressed; -Bp
SA-bipolar; -C p SA-chronic; -PO p SA–poor-outcome); PNOS p psychosis not otherwise specified; UFP p unspecified functional psychosis. Diagnoses separated by commas
constitute one model; sets separated by semicolons are alternative models over which scores were maximized; “” p plus narrower diagnoses. Some publications include data
on broader models.
d Peds p informative pedigrees; aff p genotyped affected cases.
e Nonpar p nonparametric; Dom p dominant; Rec p recessive; Dom, Rec p scores maximized over Dom and Rec analyses (for each diagnostic model) before ranking; Par
(4) p scores maximized over four parametric models.
f HLOD p heterogeneity LOD score.
g Eur p mixed European (from the United States and Europe); Eur-Am p European American; Afr-Am p African American; Ger p German; Sephp Israeli, predominantly
Sephardic; Hung p Hungarian.
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cussed in the first article in this series (Levinson et al.
2003 [in this issue]) and summarized below.
Badner and Gershon (2002a) reported a meta-analysis
of published SCZ genome scans using their multiple scan
probability (MSP) method (Badner and Gershon 2002b),
which combines P values across scans in regions with
clusters of positive scores after adjusting for the size of
the region. Differences between these methods have been
discussed in the first article in this series (Levinson et al.
2003 [in this issue]). The GSMA presented here included
studies that were not available to Badner and Gershon
(2002b) and excluded some of the studies they analyzed
(see the “Discussion” section for details); our analysis
also included data provided by the investigators for every
marker in each scan, whereas the MSP used only pub-
lished data (from scans with data in all nominally sig-
nificant regions) and substituted P values of .5 or 1.0 for
missing data points. By including only complete whole-
genome data from each scan, the present analysis may
be expected to avoid two problems inherent in publi-
cation bias: (1) investigators tend to present their most
positive results, as well as weakly positive results that
seem to confirm others’ findings, which could inflate
meta-analysis results in those regions; and (2) conversely,
GSMA can detect significant cross-study results for
regions that are weakly positive in many studies but not
sufficiently positive to have been presented as “one of
the best results” in any study.
The GSMA for SCZ has been performed under a sin-
gle narrow diagnostic model (with a few exceptions, as
described below), which includes SCZ (psychotic symp-
toms such as delusions and hallucinations and deficits
in emotional and social functioning, usually with a
chronic course) and schizoaffective disorder (mixed
schizophrenic and manic or depressive disorders with
persistence of psychosis when mood symptoms remit),
which coaggregates with SCZ in families (Levinson and
Mowry 2000). Although family study data suggest that
a broader spectrum of disorders coaggregate with SCZ
in families (Levinson and Mowry 2000), the “core”
diagnoses involving overt psychosis and chronic course
are made most reliably across research groups (Faraone
et al. 1996) and have been the focus of most linkage
studies.
If at least weak linkage is present in many or most
samples, larger samples would be expected to contribute
more information. Therefore, we consider our primary
analysis to be one in which the ranks of bins for each
scan are weighted to account for sample size, as de-
scribed below. Unweighted analyses are also reported
for comparison. This method of meta-analysis should
be most useful in detecting loci that increase disease
susceptibility in a substantial proportion of the samples
under study, although the observed effect in each sample
may be both small and variable because of stochastic
or other effects. One would not expect the method to
be useful in cases where a locus is having an effect only
in a few unique samples, such as those with specific
pedigree structures or ethnic or geographical back-
grounds. However, we have included samples collected
in more isolated populations, because the similar clinical
features and prevalence of SCZ in different cultures sug-
gest that at least some of the susceptibility loci are com-
mon to many populations (Risch 1990). We followed
the same rationale in including studies of one or a few
extended pedigrees and of many smaller pedigrees.
Material and Methods
Selection of Genome Scans and Genotyping Data
Genome scans of SCZ were identified through pub-
lications and oral presentations. Scans were selected if
DNA markers at 30 cM or finer density were typed
throughout the genome in families selected through a
proband with SCZ defined by Diagnostic and Statistical
Manual (DSM)-IIIR or DSM-IV criteria or by Research
Diagnostic Criteria (RDC) (and not through a particular
subtype), in nonoverlapping samples with at least 30
affected genotyped cases with SCZ or schizoaffective dis-
order. Partial scans and candidate region studies were
excluded. These criteria establish consistency across
studies in several important respects, including reason-
ably even marker coverage of the genome, well-estab-
lished linkage statistical methods, and the use of a di-
agnostic model with good reliability across research
teams, as well as the predominantly European ethnicity
of most of the samples; however, the studies did vary in
sample size, the degree of ethnic diversity, the number
of linkage analyses that were applied, and the density
and evenness of marker spacing. For all selected scans
(table 1), either the required data were already published
or posted on the Web, or the investigators provided the
requested data used in analyses that were published or
in press, except for the Palau study (Coon et al. 1998),
for which unpublished complete genome scan data were
provided by the investigator (W.B.).
The 20 scans were performed by 14 different research
groups in 16 projects. Straub et al. (2002b) typed three
different interdigitated 30-cM marker maps (with fol-
low-up of positive scores) in each of three pedigree sub-
sets, which were treated here as three independent scans;
the Finnish group separately analyzed families from the
general Finnish population and from a genetically iso-
lated subpopulation (Paunio et al. 2001); and the NIMH
group analyzed European American and African Amer-
ican families as separate samples (Kaufman et al. 1998;
Faraone et al. 1998). The GSMA method assumes a
uniform map in each scan, so we did not consider the
second stages of genome scans where candidate regions
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were more densely mapped or samples were modified.
For example, we used only the first-phase uniform ge-
nome scan for the Cardiff study (Williams et al. 1999).
For most scans, however, we could not achieve uniform
density, because markers had been added at various
times in candidate regions and any post hoc decision to
remove certain markers would have been biased. The
SD of the number of markers per bin ranged from close
to 1, in some studies, to 4.19. Further study will be
required to elucidate the degree of bias introduced into
GSMA by variable marker densities.
Diagnostic Models
The most common phenotypic definition included
both SCZ and schizoaffective disorders by any of the
diagnostic criteria noted above, which are historically
related and similar but not identical. For 16 of the 20
scans, we ignored any broader definitions and used only
scores from analyses that considered these two diagnoses
as affected; if the strategy had included sequential anal-
yses considering only SCZ and then adding schizoaffec-
tive cases, we maximized scores at each marker over
these two models. For one study (Garver et al. 2001),
we used scores based only on cases of SCZ, because the
alternative was a very broad definition. For three studies
(Levinson et al. 1998; Gurling et al. 2001; Lindholm et
al. 2001), the narrowest or only definition included SCZ,
schizoaffective disorder, and other “nonaffective” psy-
choses, which have been shown to coaggregate with SCZ
in families (Levinson and Mowry 2000). Note that, un-
like traditional meta-analysis methods, which typically
require an identical statistical test for each sample,
GSMA can accommodate methodological differences, as
long as each study uses an apparently valid approach to
arrive at a single score, for each marker, that can be rank
ordered across the genome. Since there were too few
studies that used each alternative definition of the phe-
notype to permit separate GSMAs (as was done for bi-
polar disorder in the following article in this series [Se-
gurado et al. 2003 {in this issue}]), we used the analysis
from each study that came closest to the predominant
diagnostic model of SCZ plus schizoaffective disorder.
If the study’s strategy involved maximizing LOD scores
over two or more diagnostic models within this range,
then we followed that approach (see table 1). One lim-
itation of the present analysis is that, in our simulation
studies presented in the first article in this series (Lev-
inson et al. 2003 [in this issue]), we did not consider the
effect on GSMA of maximizing scores over multiple di-
agnostic and/or transmission models.
Linkage Scores Used in the Rank-Ordering Procedure
For each scan, we obtained linkage scores at each
marker, the numbers of pedigrees and of affected ge-
notyped cases for the selected diagnostic models, and the
phenotypic criteria and the nature of the statistical tests
(table 1). The rank-ordering procedure (below) requires
one score for each marker. We used scores from a single
nonparametric test (e.g., maximum LOD score [MLS]
or NPL) of one diagnostic model, except as follows: for
Utah (Coon et al. 1994), Palau (W.B., unpublished data),
and Canada (Brzustowicz et al. 2000), we used the max-
imum of the dominant or recessive parametric LOD
scores for any recombination fraction and proportion of
linked families at each marker (one diagnostic model).
We use the maximum LOD score over four parametric
models (one diagnostic model) at each marker for Med-
ical College of Virginia (MCV)/Ireland (Straub et al.
2002b), over four diagnostic models (one genetic model)
for Sweden (Lindholm et al. 2001), over two “model-
free” linkage tests (minimum P values for MFLOD and
MALOD scores) for University College London (Gurling
et al. 2001), and, for Finland (Paunio et al. 2001), over
eight tests, including all combinations of two LOD
scores (dominant and recessive), two diagnostic models,
and two definitions of family structure (nuclear families,
or with connections retained between more distantly re-
lated pedigrees, which was most relevant to the isolated
population).
GSMA
GSMA (Wise et al. 1999) was performed as described
in the first article of this series (Levinson et al. 2003 [in
this issue]). Key terms are summarized in appendix A.
In brief, the autosomes were divided into 120 30-cM
bins defined by Ge´ne´thon markers (CEPH-Ge´ne´thon In-
tegrated Map Web site). On the Marshfield map (Center
for Medical Genetics Web site), the average bin width
was 29.1 cM, as shown in figure 1. Each marker was
placed within one of these bins, on the basis of its lo-
cation on the Ge´ne´thon, Marshfield, or Southampton
map (Genetic Location Database Web site) or on the
human genome map (National Center for Biotechnology
Web site). For each study, each bin was assigned a
within-study rank (Rstudy) based on the maximum linkage
score or minimum P value within the bin. Bins were
ranked in ascending order (1p most significant result).
Negative or zero scores were considered ties, and their
Rstudy values were averaged (e.g., 20 such scores would
all be assigned an Rstudy of 110.5). The average rank
across studies was then computed for each bin (RAvg).
For the weighted analysis, each Rstudy value was multi-
plied by its study’s weight ( ), dividedN[affected cases]
by the mean of this value over all studies), as discussed
in the first article in this series (Levinson et al. 2003 [in
this issue]). Two pointwise P values were determined,
PAvgRnk and Pord, as defined in appendix A. These were
computed by permutation test, as described in the first
Figure 1 Ranks by study and average ranks. The following are shown: within-study ranks (Rstudy) grouped as shown in the legend; the
average rank (Ravg) for each bin across studies (low values are best), weighted proportional to for each study; and the overallN(affected cases)
place of each bin in ascending order of average ranks (the lowest/best average rank is first place). Average ranks with significant PAvgRnk values
are highlighted above the columns (black for , gray for ). Exact PAvgRnk values are shown in table 2. Tied ranks sometimesP ! .01 P ! .05AvgRnk AvgRnk
resulted in uneven numbers of bins in some groupings, particularly for lower ranks when there were many zero or negative scores. Marshfield
(“Mfd”) locations are shown for the marker at the distal boundary of each bin. Bin boundaries were selected at ∼30 cM spacing on the Ge´ne´thon
map; mean bin width is 29.1 cM on the Marshfield map. Peds p number of pedigrees; Aff p number of genotyped affected cases. See table
1 for the references associated with each study.
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article of this series (Levinson et al. 2003 [in this issue])
(here, 5,000 permutations of the unweighted analysis
and 30,000 of the weighted analysis).
One might think of these two values by analogy in
terms of a race. Consider runner X, who finished in
fourth place. If the RAvg values in the randomly permuted
analyses might be compared to the times of many run-
ners in many previous races, then PAvgRnk is analogous
to the probability of any previous runner having run a
race at least as fast as X, and Pord is analogous to the
probability of any previous fourth-place finisher having
run a race at least as fast as X. Pord compares RAvg values
to those with the same place in the order (was this RAvg
particularly low, compared with other bins in this place
in the order?), whereas PAvgRnk is a typical pointwise P
value that ignores order.
The simulation studies presented in the first article in
this series (Levinson et al. 2003 [in this issue]) suggested
several criteria for determining the significance of GSMA
results, corrected for multiple testing (i.e., genomewide
significance). These are shown in appendix B. P !AvgRnk
(.05 corrected for 120 tests) suggests that a bin.000417
is likely to contain a linked locus or loci. A number of
aggregate criteria were also determined to suggest that
linkage is likely to present in some or all of a set of bins.
When aggregate criteria for linkage are met, bins that
have achieved both and are theP ! .05 P ! .05AvgRnk ord
most likely to contain linked loci or to be adjacent to
linked bins.
Pord can be computed by permuting ranks bin by bin
or by permuting chromosomal segments so that average
ranks for bins at the edges of chromosomes, where link-
age information is reduced, will be compared with the
distribution of other telomeric bins, as described in the
first article in this series through use of simulated data
(Levinson et al. 2003 [in this issue]). Here the by-chro-
mosome permutation procedure was not more conser-
vative, and we report Pord values that were computed by
permuting by bin within each scan.
Results
Figure 1 shows the markers at the boundaries of each
bin and their location on the Marshfield map, the av-
erage rank for each bin across all scans weighted by the
square root of the number of genotyped affected cases,
and a condensed representation of each bin’s within-
study ranks (“1” denotes , etc., as shownR p 1–5study
in the legend). A complete list of weighted and un-
weighted Rstudy and RAvg values is available at the URL
listed in the “Electronic-Database Information” section.
In the row labeled “bin” for each half of the figure, the
bins with are shaded in black, and thoseP ! .01AvgRnk
with are shaded in gray. This figure illus-P ! .05AvgRnk
trates which studies contributed the lowest ranks to the
average rank for each bin. For example, bin 2.5, which
achieved the best RAvg, had Rstudy values between 1 and
10 in 8 of 20 scans, whereas bin 3.2, with the third-best
RAvg, was ranked between 1 and 20 in only 4 scans, and
its low RAvg was due to lower Rstudy values than the av-
erage in most scans. The scans are sorted in descending
size so that the relative contributions of larger and
smaller data sets can be appreciated.
Figure 2 is a scatterplot of the weighted and un-
weighted average ranks for each bin, with solid dia-
monds representing the primary, weighted analysis, and
open diamonds representing the unweighted analysis for
comparison. The 99%, 95%, and 90% thresholds of
significance are shown; the Y-axes for the two analyses
have been adjusted so that the lines marking the thresh-
olds are the same.
Table 2 lists PAvgRnk and Pord values for weighted and
unweighted analyses for the 19 bins with either value
!.05 by either analysis. Results for the primary weighted
analysis will be discussed here and are illustrated in
figure 3. Only bin 2.5 (2p11.1-q21.1) met the criterion
for genomewide significance of . TheP ! .000417AvgRnk
nominally significant PAvgRnk of the adjacent bin, 2.6,
provides additional evidence for linkage here, because,
in simulated data, bins adjacent to those containing dis-
ease loci often also achieve nominal significance. This
bin had one of the five lowest ranks in six scans (U.S./
International, MCV/Ireland [c], U.S./Australia, NIMH-
Eur-Am, Kiel, and Palau), and ranks between 6 and 10
in two others (Cardiff and Utah).
Three aggregate criteria for genomewide significant
linkage were met:
1. Twelve bins had (shown in boldfaceP ! .05AvgRnk
italic type in table 2). This exceeds the threshold
of 11 such bins observed in !5% of simulated
whole-genome replicates of similar data sets with
no linkage present.
2. Each of these 12 bins also had , indicatedP ! .05ord
by asterisks in table 2 and illustrated in figure 3.
This exceeds the 5% empirical threshold of4 bins
with PAvgRnk and Pord values !.05 for GSMA repli-
cates of 14 or 20 studies (the threshold was 5 with
only 9 studies); 12 such bins were never observed
in 1,000 unlinked replicates of 20 studies resem-
bling those in the SCZ GSMA data set.
3. The 19 bins with the lowest average ranks had Pord
values !.05 (see fig. 3). The 5% threshold in un-
linked simulated data was 4 such values among
the 10 best bins, and a cluster of 19 was never
observed in 1,000 unlinked replicates of 20 studies.
In simulated data with linkage present, all three of
these thresholds were exceeded with increasing fre-
quency as the number of linked bins and their genetic
effect increased.
Finally, to determine whether the placement of bin
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Figure 2 Average ranks (Ravg) for 20 SCZ genome scans. Shown are the average ranks for each bin, comparing the results for the
unweighted () and weighted () analyses. PAvgRnk thresholds are shown. See table 2 for exact PAvgRnk and Pord values for the most significant
bins.
boundaries was having a critical effect on results, ad-
jacent bins were combined into 60-cM bins, for two
possible combinations (e.g., for chromosome 1, bins
12, 34, etc., and then 23, 45, etc.), for the
weighted analysis. Results were unchanged: the same
regions had nominally significant PAvgRnk P values, as are
shown in table 2 for 30-cM bins, with similar levels of
significance, and no new regions of interest were iden-
tified. Thus, it appears that the placement of bin bound-
aries did not, in this case, bias the results against any
region.
Discussion
Genomewide evidence for linkage was observed in this
meta-analysis of 20 SCZ genome scans. The average
rank of bin 2.5 (chromosome 2p12-q22.1) was associ-
ated with a genomewide significant P value after cor-
rection for multiple testing. In addition, all three em-
pirical aggregate criteria for linkage were met: more bins
than expected by chance achieved nominally significant
values of PAvgRnk (pointwise P value of the average rank),
of Pord (pointwise P value of the average rank taking into
account its place in the order of average ranks), and of
both PAvgRnk and Pord. The number of bins meeting each
of the latter two criteria was highly significant—that is,
it was greater than was observed in any of 1,000 GSMAs
of simulated whole-genome replicates of 20 similar stud-
ies (genomewide ).P ! .001
The aggregate criteria suggest that these 20 scans sup-
port linkage of multiple loci to SCZ. However, there is
no straightforward way to determine which of the im-
plicated bins represent true positive results. In simula-
tions of genomes containing 5–10 linked loci, each of
small effect, bins with nominal significance for PAvgRnk
and Pord are most likely to contain a linked locus or to
be immediately adjacent to a bin that does; when clus-
ters of bins meet this criterion, few, if any, are false
positives. Therefore, the 10 chromosomal regions rep-
resented by the first 12 bins in table 2 (marked with
asterisks) should be considered strong SCZ candidate
regions. In simulated data, both the linked bin and an
adjacent bin often achieve nominally significant PAvgRnk
and Pord, and it is possible that this phenomenon is being
observed in the pairs of significant bins on chromosomes
2q (2.5 and 2.6) and 6p (6.1 and 6.2) and perhaps also
on 1q (1.6 and 1.7), where bin 1.7 achieved a nominally
significant Pord.
Six additional chromosomal regions were included in
the cluster of 19 consecutive bins with nominally sig-
nificant values of Pord (table 2 ). In simulated data (see
table 7 in the first article in this series [Levinson et al.
2003 {in this issue}]), when there are 5–10 weakly linked
loci in the genome, there are still more unlinked than
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Table 2
PAvgRnk and Pord for Bins with the Lowest Average Ranks
BIN
MARSHFIELD
LOCATION
(Begin–End)
(cM)
CYTOGENETIC
LOCATION
UNWEIGHTED ANALYSIS WEIGHTED ANALYSIS
BOTH
P
VALUES
!.05Rank PAvgRnk Pord Rank PAvgRnk Pord
2.5 101.6–128.4 2p12-q22.1 1 .0001 .0111 1 .0004 .0327 *
5.5 131.5–164.2 5q23.2-q34 4 .0139 .0765 2 .0032 .0491 *
3.2 32.4–63.1 3p25.3-p22.1 2 .0039 .0739 3 .0060 .0311 *
11.5 99.0–123.0 11q22.3-q24.1 3 .0075 .0543 4 .0060 .0040 *
6.1 0–32.6 6pter-p22.3 7 .0220 .0101 5 .0159 .0328 *
2.6 128.4–154.5 2q22.1-q23.3 8 .0240 .0042 6 .0230 .0448 *
1.6 142.2–170.8 1p13.3-q23.3 10 .0598 .1372 7 .0235 .0136 *
22.1 0–33.8 22pter-q12.3 9 .0420 .0411 8 .0310 .0216 *
8.2 27.4–55.0 8p22-p21.1 6 .0184 .0169 9 .0310 .0068 *
6.2 32.6–65.1 6p22.3-p21.1 13 .0817 .1288 10 .0330 .0024 *
20.2 21.2–47.5 20p12.3-p11 5 .0173 .0479 11 .0460 .0098 *
14.1 0–40.1 14pter-q13.1 21 .1559 .2514 12 .0470 .0043 *
16.2 32.1–67.6 16p13-q12.2 18 .1297 .2262 13 .0560 .0069
18.4 96.5–126.0 18q22.1-qter 15 .1020 .1841 14 .0650 .0103
10.1 0–29.2 10pter-p14 24 .1818 .2706 15 .0680 .0046
1.7 170.8–201.6 1q23.3-q31.1 11 .0662 .1283 16 .0820 .0142
15.3 52.3–85.6 15q21.3-q26.1 12 .0679 .0697 17 .0950 .0293
6.4 99.0–131.1 6q15-q23.2 27 .2048 .2592 18 .0980 .0177
17.3 63.6–94.0 17q21.33-q24.3 23 .1621 .1458 19 .1120 .0349
NOTE.—Shown are data for all bins with in the weighted or unweighted analyses, plus allP ! .05AvgRnk
consecutive bins with the lowest average ranks with in the weighted analysis. Bins are sorted byP ! .05ord
their average rank in the weighted analysis. P values !.05 are highlighted in boldface italic type.
linked bins with , but these tend to be distrib-P ! .05ord
uted throughout the overall order of average ranks
rather than clustered among the best average ranks.
Thus, it is possible that some or all of these regions are
also linked to SCZ, but the support for these regions
must be considered weaker than for the cluster with
nominally significant PAvgRnk and Pord.
The simulation studies reported in the previous article
(Levinson et al. 2003 [in this issue]) did not consider a
sufficiently broad range of situations to interpret these
data more definitively. For example, we did not study
the effects on GSMA of placing two or more very
weakly linked loci in the same bin or in adjacent bins
or of varying the genetic effect of multiple linked loci.
However, the single-bin and aggregate criteria for ge-
nomewide significance discussed above were validated
by data from simulations of genomes with no linkage
present, so that these conclusions do not depend on the
comprehensiveness of the simulations that assumed
linkage.
Data for the unweighted analysis, with each study
weighted equally, are shown in table 2 for comparison.
Genomewide significance was still observed for bin 2.5.
Only 9 bins had nominally significant PAvgRnk values,
fewer than the aggregate significance threshold of 11,
but 6 of the best 10 bins had both PAvgRnk and Pord values
!.05. In discussions among the authors and with col-
leagues, it has been debated whether small studies with
larger numbers of cases per pedigree should be given
relatively more weight, because of the possible advan-
tages of such pedigrees for linkage analysis. The un-
weighted analysis can be considered the most extreme
possible alternative, in that the smallest study is
weighted equally with the largest study, but it produced
less evidence for linkage in most regions, including those
that have been supported by studies of larger pedigrees.
These data do not exclude the possibility that other
chromosomal regions harbor SCZ susceptibility loci
that could not be detected by the present methods or
that substantially influence risk in only one or a few
populations. GSMA does not currently consider X or
Y chromosome data, so no conclusions can be reached
concerning possible linkage on those chromosomes
(DeLisi et al. 2000). There are many other limitations
to our analysis—for example, we made decisions about
multiple tests (we maximized over them), subdivided
data sets (we considered them separate scans), used only
the first stage of two-stage scans, accepted variable map
density both within and across studies, as well as var-
iable numbers of incomplete families (missing parents),
and, in some cases, used data with denser maps of cer-
tain candidate regions. It is possible that other decisions
regarding these or other issues would have produced
different and perhaps more accurate results.
Regarding variable marker density, the mean number
of markers genotyped in the 12 bins with P ! .05AvgRnk
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Figure 3 SCZ average ranks versus random distribution. The blackened diamonds () denote the weighted average ranks (Ravg) for the
bins with the best (i.e., lowest) 19 ranks in the SCZ GSMA, sorted in order of Ravg. Bin numbers are labeled in boldface type for bins with
PAvgRnk and and labeled in normal type for bins with only . The gray data points indicate the mean Ravg for each ordered binP ! .05 P ! .05ord ord
(first place, second place, etc.) in 5,000 randomly permuted replicates, and the vertical gray bars represent 2 SDs above and below these means.
The figure illustrates how, for this cluster of 19 bins, average ranks are significantly lower than expected from the random distribution. See
table 2 for exact P values and cytogenetic locations of the best 19 bins.
was 5.21, versus 3.1 for all other bins ( ;tp 3.39 Pp
). Wise (2000) simulated an unlinked 30-cM region.006
in 120 sib pairs (10 markers, 500 replicates). Multipoint
sib pair analysis using 3, 5, 7, or 10 markers yielded
mean maximum MLS values (within the bin) of 0.272,
0.333, 0.373, and 0.385, respectively, because of in-
creasing SDs. A GSMA could thus be biased by extreme
variation in density, especially if there was biased se-
lection of regions (e.g., increased density in candidate
regions only where positive scores had been observed
by chance). In the present data, the densest typing was
in a few studies that first reported evidence for linkage
in a region; however, because the bin had one of the
best ranks before the extra markers were typed, the
biasing effect should be small. For example, in bin 6.1,
mean coverage was 8.65 markers, but without the Bonn
and three MCV/Ireland scans (18–27 markers) the mean
was 4.85. For bin 22.1, the mean was 6.85, but without
Johns Hopkins, U.S./International, and Bonn (13–16
markers) it was 4.82. However, this type of bias was
not systematically studied here, and an effect cannot be
ruled out. Future investigators should be aware that it
is advantageous to perform an initial analysis of a
screening map with uniform spacing prior to adding
additional markers in candidate regions.
One previous meta-analysis of SCZ genome scan data
(Badner and Gershon 2002a) applied a method for com-
bining P values from many of these studies and found
significant results on chromosomes 8p and 13q. They
analyzed published results, whereas we obtained linkage
data for all markers from each investigator, to permit
detection of evidence for linkage in regions that had not
come to attention because scores were not strikingly
positive. The differences in results could also have been
due primarily to the use of different sets of scan anal-
yses. Badner and Gershon (2002a) included nine data
sets that were used in this analysis (Bonn, Canada, Johns
Hopkins, Kiel, the two NIMH scans, U.K./Iceland, U.S./
Australia, and Utah), a different data set for one scan
(the second-stage analysis of candidate regions in the
Cardiff scan, using an enlarged sample), incomplete
data for four scans (U.S./International, the two Finnish
scans, and Sweden), no data for six scans (the three
MCV/Ireland subsets, and the Costa Rica, Texas, and
Palau scans), and data from four scans that we excluded
because of small sample size (Bailer et al. 2002), in-
complete genome coverage (Barr et al. 1994), selection
of probands for periodic catatonia rather than SCZ
(Stober et al. 2000), or possible overlap with another
sample (Rees et al. 1999) leading us to include the larger
sample (Williams et al. 1999). The same region of chro-
mosome 8p was significant in both analyses, and it
seems understandable that we identified additional sig-
nificant regions with a larger data set and more complete
data. It is more difficult to explain why the 13q region
was highly significant in the Badner and Gershon
(2002a) analysis but did not approach significance here.
Evidence for a susceptibility gene in this region has re-
cently been published (Chumakov et al. 2002) and
awaits confirmation.
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In the present analysis, bin 2.5 (2p11.1-q21.1) had
the best average rank (31.8), with a genomewide sig-
nificant . This bin had ranks between 1P p .0004AvgRnk
and 5 in six scans (U.S./International, MCV/Ireland [c],
U.S./Australia, NIMH-Eur-Am, Kiel, and Palau) and
had ranks between 6 and 10 in two scans (Cardiff and
Utah). DeLisi et al. (2002b) observed slightly more pos-
itive results in bin 2.4, with the peak MLS in the initial
genome scan at the boundary marker for bins 2.4 and
2.5 (D2S139), whereas the other scans with high ranks
in this region maximized within bin 2.5 or the more
distal bin 2.6.
Among the other bins listed in table 2, previous find-
ings on chromosomes 6p and 8p have been discussed
in the Introduction. For 6p, maximal evidence for link-
age was in bin 6.1 (Lindholm et al. 2001; Straub et al.
2002b) or 6.2 (Schwab et al. 2000), whereas all of the
highly positive linkage reports on 8p have been in bin
8.2 (Kendler et al. 1996; SLCG 1996; Blouin et al. 1998;
Brzustowicz et al. 1999), except for the linkage peak
and candidate gene locus (NRG1) reported recently by
Stefansson et al. (2002), which are in bin 8.3. Positive
findings in bin 5.5 have previously been presented by
Straub et al. (1997) and by Schwab et al. (1997). Pulver
et al. (1995) reported a modestly positive LOD score
on chromosome 3p in bin 3.1, whereas the current find-
ing is in bin 3.2; a multicenter study that found no
evidence for linkage on 3p (SLCG 1996) did not include
all of bin 3.2. Gurling et al. (2001) reported evidence
for linkage in bin 11.5. On chromosome 1q, the max-
imum evidence for linkage reported by Brzustowicz et
al. (2000) was in bin 1.6, and the nearby peak reported
by Gurling et al. (2001) was in bin 1.7. Bin 22.1 on
chromosome 22q contains the deletion region for velo-
cardio-facial syndrome, which is associated with schizo-
phrenic symptoms (Pulver et al. 1994b; Karayiorgou et
al. 1995; Murphy et al. 1998) and which came to the
attention of the field after Pulver et al. (1994a) reported
modestly positive evidence for linkage in the region.
Chiu et al. (2002) reported an interaction between link-
age at markers in bins 8.2 and 14.1 in the Johns Hop-
kins data set.
Among the bins in the cluster of nominally significant
Pord values, bin 10.1 had one of the highest ranks in
four scans (U.S./International, MCV/Ireland [a], Bonn,
and NIMH-Eur-Am) and had been proposed as a can-
didate region by Faraone et al. (1998), Schwab et al.
(1998), and Straub et al. (1998), with a multicenter
study providing only weak support (Levinson et al.
2000). Bin 6.4 contains the region of chromosome 6q
discussed above. No previous reports have called atten-
tion to chromosomes 16p-q, 15q, or 17q as SCZ can-
didate regions. Bin 15.3 is considerably distal to the
location of the a-7-nicotinic receptor in bin 15.1 (Freed-
man et al. 1997), where positive evidence for linkage
to SCZ has been reported (Freedman et al. 2001a,
2001b; Gejman et al. 2001; Tsuang et al. 2001).
It is of interest that, in several cases, the GSMA pro-
vided support for linkages that had been observed pre-
viously in small samples of extended pedigrees from more
homogeneous or isolated populations (e.g., regions of
chromosomes 1q, 2q, 6q, and 11q, as discussed above),
despite the fact that the weighting procedure greatly re-
duced the contributions of these smaller samples to the
results. This supports the hypothesis that there are at least
some loci that contribute to SCZ susceptibility in many
or most populations and that loci whose effects are de-
tected particularly strongly in a unique population may
also prove relevant in many other populations.
In conclusion, we can suggest with considerable con-
fidence that SCZ susceptibility loci are likely to exist in
some or all of the chromosomal regions noted above.
A meta-analysis is one step toward defining genomic
regions that harbor SCZ susceptibility loci. Investiga-
tors might wish to consider performing collaborative
linkage analyses using raw genotypes and integrated
marker maps or regenotyping available pedigrees with
a common, dense map. Investigators of other complex
disorders might be further stimulated to collaborate in
various ways, to study larger data sets. Additional de-
tails of the present analysis, including ranks for each
study, are available at the University of Pennsylvania
Web site listed in the Electronic-Database Information
section. These results are cause for considerable opti-
mism about the prospects for identifying SCZ suscep-
tibility genes.
We plan to update this analysis when several new
SCZ genome scans are completed, and we invite inves-
tigators with new genome scan data to contact the pres-
ent authors.
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Appendix A
Summary of Terminology
Bin: One of 120 30-cM autosomal segments used as
units of analysis in GSMA; bin 2.1 is the first 30 cM of
chromosome 2.
Rstudy (within-study rank): The rank of each bin within
a single study, based on the maximum linkage score (or
lowest P value) within it. The bin containing the best
score has a rank of 1. All negative and 0 scores are
considered to be tied. For weighted analyses, each raw
rank is multiplied by the study’s weighting factor.
RAvg (average rank): The average of a bin’s within-
study ranks or weighted ranks across all studies.
PAvgRnk (probability of RAvg): The pointwise probability
of observing a given RAvg for a bin in a GSMA of N
studies, determined by theoretical distribution (un-
weighted analysis only) or by permutation test.
Pord (probability of RAvg given the order): The point-
wise probability that, for example, a first-place, second-
place, third-place, etc., bin would achieve RAvg at least
this extreme in a GSMA of N studies.
Genomewide significance: For , correctionap 0.05
for 120 bins yields a threshold for genomewide signifi-
cance of .000417 for PAvgRnk or Pord. For suggestive link-
age (a result observed once per scan by chance), ap
.1/120p 0.0083
Appendix B
Criteria for Genomewide Significance
For individual bins, the criterion for genomewide sig-
nificance is . When linkage is likely toP ! .000417AvgRnk
be present in one or more bins, the aggregate criteria
are as follows:11 bins with ,4 bins withP ! .05AvgRnk
among the 10 best values of RAvg, or 5 binsP ! .05ord
with and . Bins withP ! .05 P ! .05 P ! .05AvgRnk ord AvgRnk
and are most likely to contain linked loci. NoP ! .05ord
valid combined significance criterion was identified.
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.ncbi.nlm.nih.gov/Omim/ (for SCZD)
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